# Phase 2 lung cancer trials recruiting: 165 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 165 trials in phase 2 for lung cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 lung cancer trials: 165 rows for $8.25, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 4 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lung-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 165
- Recruiting or not yet: 165
- Read on: November 19, 2026

## Trials

The 25 newest of 165, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07946848 | Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC. | Immuneering Corporation | Phase 2 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), Non-Squamous Non Small Cell Lung Cancer, Metastatic Non-Small Lung Cell... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07946848) |
| November 13, 2026 | NCT07936578 | Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer | Guizhou Medical University | Phase 2 | Not yet recruiting | Concurrent Chemoradiotherapy, Immunotherapy, Lung Cancer (NSCLC) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07936578) |
| October 22, 2026 | NCT07890636 | Adebrelimab Plus Famitinib as Adjuvant Therapy in Non-pCR NSCLC | Ruijin Hospital | Phase 2 | Not yet recruiting | Lung Neoplasm Malignant | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890636) |
| October 16, 2026 | NCT07878871 | Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II Study | Hunan Province Tumor Hospital | Phase 2 | Not yet recruiting | Lung Adenocarcinoma, Stage III Lung Cancer, EGFR Positive Non-small Cell Lung Cancer | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07878871) |
| October 14, 2026 | NCT07874464 | Prospective Phase II Study of Concurrent Radiotherapy Combined With Full-Course Immunotherapy or Consolidation Immunotherapy for Locally... | Sun Yat-sen University | Phase 2 | Not yet recruiting | Lung Cancer (NSCLC) | 256 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874464) |
| October 5, 2026 | NCT07858253 | CLEAR-Lung III: Circulating Tumor DNA-Guided Consolidation Chemotherapy and Immunotherapy | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Lung Cancer | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858253) |
| September 29, 2026 | NCT07848243 | Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes | Peking University Cancer Hospital & Institute | Phase 2 | Recruiting | Lung Cancer (NSCLC), Cervical Squamous Cell Cancer, Melanoma (Skin Cancer), Breast Cancer, Gastrointestinal Cancers | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07848243) |
| September 23, 2026 | NCT07835789 | Testing Repeat Radiation Therapy for Recurrent Non-small Cell Lung Cancer | NRG Oncology | Phase 2 | Not yet recruiting | Locally Recurrent Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8 | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07835789) |
| September 21, 2026 | NCT07829744 | Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations | Shanghai Zhongshan Hospital | Phase 2 | Not yet recruiting | Lung Cancer (NSCLC) | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829744) |
| September 14, 2026 | NCT07818304 | SRT Combined With Envafolimab and Endostar in the First-line Treatment of Advanced NSCLC | The First People's Hospital of Lianyungang | Phase 2 | Not yet recruiting | Non Small Cell Lung Cancer, Lung Neoplasms | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07818304) |
| September 3, 2026 | NCT07802834 | Adjuvant ctDNA-Adapted Treatment With Zipalertinib in Early-Stage Atypical EGFR-Mutant NSCLC | Stanford University | Phase 2 | Not yet recruiting | EGFR, Lung Cancer (NSCLC), Non Small Cell Lung Cancer | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07802834) |
| August 20, 2026 | NCT07777614 | OPTIMISE Lung SABR | Cancer Trials Ireland | Phase 2 | Recruiting | Non Small Cell Lung Cancer | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777614) |
| August 4, 2026 | NCT07745790 | Safety and Efficacy of Multimodal Thermal Therapy (MTT) Combined With KRAS G12V mRNA Vaccine, S-1, and Sintilimab in Patients With... | Ruijin Hospital | Phase 2 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma, Liver Neoplasms, Lung Neoplasms | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07745790) |
| July 23, 2026 | NCT07722182 | Navigation Bronchoscopy Guided Microwave Ablation Versus SBRT in Early NSCLC | Chinese University of Hong Kong | Phase 2 | Not yet recruiting | Lung Cancer (NSCLC) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722182) |
| July 22, 2026 | NCT07718672 | Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small... | Roswell Park Cancer Institute | Phase 2 | Recruiting | Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718672) |
| July 13, 2026 | NCT07699952 | First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for... | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Lung Cancer (NSCLC), EGFR Activating Mutation, HER2 | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07699952) |
| July 6, 2026 | NCT07685938 | Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Chest Wall Tumor, Breast Cancer, Lung Cancer, Esophageal Cancer, Mediastinal Cancers, Spine Metastases, Spinal Tumor... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07685938) |
| July 1, 2026 | NCT07679607 | GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung | University of Maryland, Baltimore | Phase 2 | Not yet recruiting | Lung Cancer (NSCLC), Radiation | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07679607) |
| June 5, 2026 | NCT07630168 | Effects of Infusion Timing on Treatment Response in Solid Tumors | UNC Lineberger Comprehensive Cancer Center | Phase 2 | Recruiting | Lung Cancer, Non-small Cell Lung Cancer, Metastatic Lung Cancer, Head and Neck Cancer, Metastatic Squamous Cell... | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07630168) |
| June 1, 2026 | NCT07617246 | The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by... | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Esophagus Cancer, Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617246) |
| May 22, 2026 | NCT07603856 | A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer | University of Chicago | Phase 2 | Recruiting | Non-Small Cell Lung Cancer, Metastatic Lung Cancer | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07603856) |
| May 14, 2026 | NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or... | Peking University People's Hospital | Phase 2 | Recruiting | Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586826) |
| May 8, 2026 | NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | Fred Hutchinson Cancer Center | Phase 2 | Not yet recruiting | Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07576725) |
| May 1, 2026 | NCT07561645 | A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the Lung | Technische Universität Dresden | Phase 2 | Not yet recruiting | Large Cell Neuroendocrine Carcinoma of the Lung | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07561645) |
| April 21, 2026 | NCT07543172 | CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer | Roswell Park Cancer Institute | Phase 2 | Not yet recruiting | Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8 | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07543172) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 8 |
| Shanghai Pulmonary Hospital, Shanghai, China | 6 |
| M.D. Anderson Cancer Center | 4 |
| The First Affiliated Hospital of Guangzhou Medical University | 4 |
| Roswell Park Cancer Institute | 4 |
| University of Washington | 4 |
| City of Hope Medical Center | 3 |
| Mayo Clinic | 3 |
| UNC Lineberger Comprehensive Cancer Center | 3 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 3 |
| Sichuan University | 3 |
| Tianjin Medical University Cancer Institute and Hospital | 3 |
| University of Chicago | 3 |
| SWOG Cancer Research Network | 3 |
| Second Affiliated Hospital of Guangzhou Medical University | 3 |
| Cancer Trials Ireland | 2 |
| Memorial Sloan Kettering Cancer Center | 2 |
| National Cancer Institute (NCI) | 2 |
| University of Maryland, Baltimore | 2 |
| Avistone Biotechnology Co., Ltd. | 2 |
| Chinese University of Hong Kong | 2 |
| Emory University | 2 |
| Ruijin Hospital | 2 |
| Fundación GECP | 2 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |

## By country

| Country | Trials |
| --- | --- |
| United States | 69 |
| China | 60 |
| Spain | 12 |
| France | 9 |
| Italy | 9 |
| Taiwan | 9 |
| Canada | 8 |
| Germany | 7 |
| Australia | 7 |
| South Korea | 6 |
| Hong Kong | 5 |
| Japan | 5 |
| Hungary | 5 |
| Israel | 5 |
| Ireland | 4 |
| Belgium | 4 |
| Turkey (Türkiye) | 4 |
| Netherlands | 4 |
| United Kingdom | 4 |
| Switzerland | 3 |
| Poland | 3 |
| Norway | 2 |
| Chile | 2 |
| Greece | 2 |
| Brazil | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pediatric endocrinology practices in the United States](https://specstream.ai/data/businesses/pediatric-endocrinology-practices/united-states)
- [Specialty hospitals in the United States](https://specstream.ai/data/businesses/specialty-hospitals/united-states)
- [Afghani restaurants in the United States](https://specstream.ai/data/businesses/afghani-restaurants/united-states)
- [Business office supplies and stationery companies in the United States](https://specstream.ai/data/businesses/business-office-supplies-and-stationery-companies/united-states)
- [Empanada restaurants in the United States](https://specstream.ai/data/businesses/empanada-restaurants/united-states)
- [Hyperbaric medicine centers in the United States](https://specstream.ai/data/businesses/hyperbaric-medicine-centers/united-states)
